EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Meningitis burden and vaccine impact in the WHO Western Pacific Region, 1990–2023

Seungjae Byun, Yeongtaek Hwang, Yejun Son, Taelim Choi, Hyeon Jin Kim, Lee Smith, Ho Geol Woo, Christa J Nehs, Dong Keon Yon, Jiseung Kang

Journal of Travel Medicine · 2026-10-30 · 33 (7)

DOI: 10.1093/jtm/taag083 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background Meningitis remained a major cause of death and disability worldwide, but evidence on long-term trends, pathogen distribution and the impacts of the vaccine program across the World Health Organization (WHO) Western Pacific Region (WPR) remained limited. Methods We used the WHO Immunization Data and the Global Burden of Diseases Study (GBD) 2023 for the period 1990–2023. We assessed the incidence and mortality of meningitis across 32 WPR countries. Incidence and mortality were analysed by age, sex and 17 pathogens, with age-standardized rates calculated using the GBD global standard population. To evaluate the impact of the vaccine program, we applied negative binomial generalized linear models with a log link function and population offset to annual pathogen-specific death counts, characterizing vaccine exposure by program introduction and annual coverage. Results From 1990 to 2023, incident cases of meningitis in the WPR declined from 638.02 thousand [95% uncertainty interval (UI), 497.54–789.94] to 162.67 thousand (136.19–192.51), and deaths declined from 78.16 thousand (55.76–103.50) to 15.17 thousand (11.45–21.03), although marked between-country disparities persisted. Streptococcus pneumoniae, Neisseria meningitidis and Haemophilus influenzae accounted for the greatest number of meningitis-related deaths, although their burden declined over time. H. influenzae type b (Hib3) introduction was associated with a 31.85% reduction in H. influenzae meningitis deaths across the WPR (95% CI, −39.40 to −23.35%), and pneumococcal conjugate (PCV3) introduction with an 11.53% reduction in S. pneumoniae meningitis deaths (95% CI, −21.20 to −0.68%). Under a counterfactual scenario of 95% vaccine coverage, H. influenzae meningitis deaths were projected to further decline by 14.82% (95% CI, 7.33–21.41%), and S. pneumoniae meningitis deaths by 12.27% (2.43–20.92%). Conclusions The burden of meningitis in the WPR declined substantially from 1990 to 2023, but persistent cross-country inequalities and shifts in age-specific and pathogen-specific patterns remained. Hib3 and PCV3 vaccine introductions were associated with meaningful reductions in vaccine-targeted meningitis mortality, though the effect varied across countries.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →